Effects of atorvastatin and rosuvastatin on blood lipids, platelet aggregation rate and inflammatory factors in patients with cerebral infarction
Abstract
Purpose: To investigate the effects of atorvastatin and rosuvastatin on blood lipids, platelet aggregation rate (PAR) and inflammatory factors in patients with cerebral infarction.
Methods: Patients (n = 120) with cerebral infarction treated in Feng Hua People's Hospital, Jiang Feng Hua, China from January 2014 to October 2016 were randomly divided into control group (clopidogrel combined with atorvastatin, 60 cases) and observation group (clopidogrel combined with rosuvastatin, 60 cases). Blood lipids, PAR, inflammatory factors and carotid atherosclerotic plaque were recorded and compared.
Results: Following treatment, total cholesterol (TC), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) in the observation group were significantly lower (p < 0.05) than in the control group, while high density lipoprotein cholesterol (HDL-C) was significantly higher (p < 0.05). C-reactive protein (CRP), tumor necrosis factor-α (IL-6) and interleukin-6 (IL-6) were significantly decreased in the two groups after treatment (p < 0.05). Plaque area, intima-media thickness (IMT) and number of plaques in the two groups were significantly lower after treatment than before treatment (p < 0.05). Plaque area, IMT and number of plaques in the observation group were significantly lower than those in the control group (p < 0.05).
Conclusion: Atorvastatin and rosuvastatin have no significant effect on the antiplatelet function of clopidogrel, but rosuvastatin shows better control of blood lipids, carotid atherosclerosis and inflammatory factors.
Keywords: Atorvastatin, Rosuvastatin, Cerebral infarction, Blood lipids, Platelet aggregation rate, Inflammatory factors
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
